Neurologic status\r\n* Patients with neurological deficits should have deficits that are stable for a minimum of  week prior to enrollment\r\n* Patients with seizure disorders may be enrolled if seizures are well controlled on an anti-epileptic drug that is not a strong inducer or inhibitor of CYPA/ are eligible
Patients with neurological deficits should have deficits that are stable for a minimum of  week prior to registration
Patients with neurological deficits should have deficits that are stable for a minimum of  week prior to registration
Patients with neurological deficits should have deficits that are completely stable for a minimum of  week ( days) prior to enrollment
INCLUSION CRITERIA FOR STRATUM C: Patients with neurological deficits should have deficits that are completely stable for a minimum of  week ( days) prior to enrollment
Patients with neurological deficits that are stable for a minimum of one week prior to registration
Any neurologic deficits must be stable for >=  week
RETREATMENT WITH MODIFIED T-CELLS INCLUSION CRITERIA: Research participant without clinically significant encephalopathy/new focal neurologic deficits
Patients with neurological deficits should have deficits that are stable for a minimum of  week prior to registration
Patients with neurological deficits should have deficits that are stable for a minimum of  weeks prior to registration
Cerebrovascular accident (CVA) with persistent neurologic deficits occurring within  months prior to enrollment; persisting neurologic deficits from a CVA occurring over  months prior to enrollment are not necessarily grounds for exclusion
Stable neurologic deficits on a stable dose of corticosteroids (if applicable) for at least  week before study enrollment
At the time of study enrollment patients must have a life expectancy of greater than or equal to  months; neurologic deficits in patients with CNS tumors must have been relatively stable for a minimum of  week prior to study enrollment
ELIGIBILITY CRITERIA FOR T-CELL PRODUCT INFUSION: Research participant without clinically significant encephalopathy/new focal neurologic deficits
RETREATMENT WITH MODIFIED T CELLS: Research participant without clinically significant encephalopathy/ new focal neurologic deficits
Neurologic deficits must have been relatively stable for a minimum of  week prior to study enrollment
Research participant without clinically significant encephalopathy/new focal deficits
(ELIGIBILITY CRITERIA AT TIME OF INFUSION OF GENETICALLY MODIFIED AUTOLOGOUS T CELLS): Research participant without clinically significant encephalopathy/new focal deficits
Research participants without clinically significant encephalopathy/new focal deficits
Research participant without clinically significant encephalopathy/new focal deficits
Neurological: research participant without clinically significant encephalopathy/new focal deficits
Patients with neurological deficits should be stable for a minimum of  week prior to enrollment
Patients with neurological deficits should have deficits that are stable or improving for a minimum of  week prior to registration
Neurologic status\r\n* Patients with neurological deficits should have deficits that are stable for a minimum of  week prior to enrollment\r\n* Patients with seizure disorders may be enrolled if seizures are well controlled
Eastern Cooperative Oncology Group (ECOG) performance status =<  (Karnofsky >= %) unless due to neurologic deficits caused by CNS lymphoma with the following exceptions: patients with ECOG performance status (PS) =  where neurologic deficits are unlikely to resolve with tumor resolution and may cause clinical management problems are excluded
Subjects with central nervous system (CNS) (or leptomeningeal) infiltration by AML may be considered for treatment at the Investigators discretion and following discussion with the Principle Investigator; all neurologic deficits must be noted prior to enrollment on study
Any active neurologic and/or psychiatric disease, history of significant head trauma followed by persistent neurologic deficits, or known structural brain abnormalities
Research participant without clinically significant encephalopathy/new focal deficits
Patient with multiple, serious major neurologic deficits including encephalopathy.
Any neurologic deficits must be stable for >=  week
Neurologic deficits that are rapidly progressing: all neurologic signs and symptoms must have been stable for a week prior to first dose
Any neurologic deficits must be stable for >=  week
Neurologic deficits that are rapidly progressing; all neurologic signs and symptoms must have been stable for a week prior to first dose
DONOR: Severe neurologic deficits
Patients with neurological deficits should have deficits that are stable for a minimum of  week prior to registration; this is to be documented at baseline
Neurologic deficits: Patients with central nervous system (CNS) tumors must have stable neurological deficits for a minimum of  week prior to study entry
For patients with CNS tumors (primary or metastatic), any baseline neurologic deficits (including seizure) must be stable for at least one week prior to study enrollment
(Patient participation) Normal cognitive status, defined as a normal state of arousal and an absence of obvious clinical findings of confusion, memory deficits or concentration deficits, as determined by the patient's physician
No orthopedic restrictions or neurologic deficits that would limit ability to complete the Power Protocol (based on the opinion of the investigator)
Neurocognitive deficits that impair ability to give informed consent
